These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Plasmapheresis: a new treatment modality for the patient with severe myasthenia gravis. Eppel M; Streib EW Nebr Med J; 1982 Apr; 67(4):72-4. PubMed ID: 7088214 [No Abstract] [Full Text] [Related]
5. Plasmapheresis therapy in myasthenia gravis. Dau PC Muscle Nerve; 1980; 3(6):468-82. PubMed ID: 7453714 [TBL] [Abstract][Full Text] [Related]
6. Azathioprine in the treatment of myasthenia gravis. Witte AS; Cornblath DR; Parry GJ; Lisak RP; Schatz NJ Ann Neurol; 1984 Jun; 15(6):602-5. PubMed ID: 6742794 [TBL] [Abstract][Full Text] [Related]
7. [Myasthenia gravis and visceral lupus erythematosus]. Truniger B Schweiz Med Wochenschr; 1979 Dec; 109(47):1847-51. PubMed ID: 394318 [TBL] [Abstract][Full Text] [Related]
8. Plasmapheresis in myasthenia gravis. Dau PC Prog Clin Biol Res; 1982; 88():265-85. PubMed ID: 7100216 [TBL] [Abstract][Full Text] [Related]
9. Response to plasmapheresis and immunosuppressive drug therapy in sixty myasthenia gravis patients. Dau PC Ann N Y Acad Sci; 1981; 377():700-8. PubMed ID: 6951494 [No Abstract] [Full Text] [Related]
10. Symposium on therapeutic controversies. Myasthenia gravis. Steroids and immunosuppressive drugs. Johns TR; Howard FM Trans Am Neurol Assoc; 1978; 103():278-81. PubMed ID: 229611 [No Abstract] [Full Text] [Related]
11. [Usefulness of plasmapheresis before thymectomy in the management of myasthenia gravis]. Iváñez V; Díez-Tejedor E; Lara M; Barreiro P Neurologia; 1994; 9(7):277-81. PubMed ID: 7946422 [TBL] [Abstract][Full Text] [Related]
12. Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis. Bromberg MB; Wald JJ; Forshew DA; Feldman EL; Albers JW J Neurol Sci; 1997 Sep; 150(1):59-62. PubMed ID: 9260858 [TBL] [Abstract][Full Text] [Related]
13. The course of myasthenia gravis in patients treated with corticosteroids, azathioprine, and plasmapheresis. Cornelio F; Peluchetti D; Mantegazza R; Sghirlanzoni A; Collarile C Ann N Y Acad Sci; 1987; 505():517-25. PubMed ID: 3479934 [No Abstract] [Full Text] [Related]
14. [Treatment of myasthenia gravis by immunosuppressive non-steroidal drugs]. De Assis JL; Marchiori PE; Scaff M; Zambon AA Arq Neuropsiquiatr; 1986 Jun; 44(2):109-16. PubMed ID: 3800686 [TBL] [Abstract][Full Text] [Related]
15. Factors influencing the relapse risk at steroid dose reduction in myasthenia gravis. Scherpbier HJ; Oosterhuis HJ Clin Neurol Neurosurg; 1987; 89(3):145-50. PubMed ID: 3665287 [TBL] [Abstract][Full Text] [Related]
16. High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies. Lin PT; Martin BA; Weinacker AB; So YT Muscle Nerve; 2006 Mar; 33(3):433-5. PubMed ID: 16116645 [TBL] [Abstract][Full Text] [Related]
17. [Favorable results of plasmapheresis in severe myasthenia gravis]. Blom RJ; Kuks JB; Westerterp-Maas A; Oosterhuis HJ Ned Tijdschr Geneeskd; 1997 Feb; 141(8):381-4. PubMed ID: 9157298 [TBL] [Abstract][Full Text] [Related]